cilostazol has been researched along with cyclic gmp in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashikaga, T; Kishi, Y; Numano, F | 1 |
| Hagiwara, M; Hidaka, H; Watanabe, Y | 1 |
| Hagiwara, M; Hidaka, H; Ishikawa, T; Itoh, H; Onoda, K; Tanaka, T | 1 |
| Ito, M; Konishi, T; Kozeki, H; Masuoka, H; Nakano, T; Sugioka, M; Tanaka, T | 1 |
| Harada, K; Kobayashi, S; Nagakura, N; Saeki, T; Saito, I; Yamanaka, T; Yoshitake, S | 1 |
| Bingaman, S; Huxley, VH; Wang, J | 1 |
| Ahluwalia, A; Duchene, J; Hattori, N; Milsom, AB; Panayiotou, C; Urabe, T; Yamashiro, K | 1 |
| Baba, T; Iyoda, M; Kasamatsu, A; Ogawara, K; Saito, Y; Sakamoto, Y; Sakuma, K; Shiiba, M; Tanzawa, H; Usukura, K; Uzawa, K | 1 |
| Carøe Nordgaard, J; Gammeltoft, S; Kruse, LS; Kruuse, CR | 1 |
| Abdel-Aziz, AM; Abdel-Gaber, SA; Rifaai, RA | 1 |
2 review(s) available for cilostazol and cyclic gmp
| Article | Year |
|---|---|
Clinical studies of phosphodiesterase inhibitors for cardiovascular disease.
Topics: Adult; Aged; Animals; Cardiovascular Diseases; Cilostazol; Cyclic AMP; Cyclic GMP; Female; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Plethysmography; Rabbits; Tetrazoles | 1992 |
[Trend in the development of new inhibitors of cyclic nucleotide metabolism and their clinical application].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cilostazol; Cyclic AMP; Cyclic GMP; Depression, Chemical; Isoquinolines; Nicardipine; Platelet Aggregation Inhibitors; Tetrazoles; Vasodilator Agents; Vinca Alkaloids | 1991 |
8 other study(ies) available for cilostazol and cyclic gmp
| Article | Year |
|---|---|
Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aorta, Thoracic; Azoles; Bucladesine; Calcium; Cilostazol; Colforsin; Cyclic AMP; Cyclic GMP; In Vitro Techniques; Muscle Contraction; Muscle, Smooth, Vascular; Rabbits; Tetrazoles; Vasodilator Agents | 1988 |
Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aorta; Blood Platelets; Calcium; Calmodulin; Cardiotonic Agents; Cilostazol; Cyclic AMP; Cyclic GMP; Enoximone; Humans; Isoenzymes; Kidney; Myocardium; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyrazines; Quinolines; Tetrazoles | 1993 |
Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
Topics: Blood Platelets; Cilostazol; Cyclic AMP; Cyclic GMP; Cyclooxygenase Inhibitors; Fatty Acids, Monounsaturated; Humans; In Vitro Techniques; Isoenzymes; Male; Papaverine; Phosphodiesterase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Tetrazoles; Thromboxane A2 | 1996 |
Intrinsic sex-specific differences in microvascular endothelial cell phosphodiesterases.
Topics: Animals; Cells, Cultured; Cilostazol; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Endothelium, Vascular; Female; Male; Microcirculation; Models, Animal; Muscle, Skeletal; Phosphodiesterase 3 Inhibitors; Phosphodiesterase I; Phosphodiesterase Inhibitors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sex Characteristics; Tetrazoles | 2010 |
Alterations in nitric oxide and endothelin-1 bioactivity underlie cerebrovascular dysfunction in ApoE-deficient mice.
Topics: Animals; Aorta; Apolipoproteins E; Cells, Cultured; Cilostazol; Cyclic GMP; Endothelin-1; Endothelium, Vascular; Humans; Hypercholesterolemia; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Cerebral Artery; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitrites; Phosphodiesterase Inhibitors; Tetrazoles; Vasoconstriction; Vasodilation | 2010 |
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Carcinoma, Squamous Cell; Cilostazol; Cisplatin; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Gene Silencing; HeLa Cells; Humans; Mice; Mice, Nude; Phosphodiesterase 3 Inhibitors; RNA, Messenger; Tetrazoles; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Role of Ser102 and Ser104 as regulators of cGMP hydrolysis by PDE5A.
Topics: Amino Acid Substitution; Calcitonin Gene-Related Peptide; Catalytic Domain; Cell Line; Cilostazol; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; In Vitro Techniques; Models, Molecular; Nitroglycerin; Phosphodiesterase Inhibitors; Piperazines; Purines; Serine; Sildenafil Citrate; Sulfonamides; Sumatriptan; Tetrazoles | 2014 |
Possible mechanisms mediating the protective effect of cilostazol in L-arginine induced acute pancreatitis in rats: role of cGMP, cAMP, and HO-1.
Topics: Animals; Arginine; Cilostazol; Cyclic AMP; Cyclic GMP; Heme Oxygenase (Decyclizing); Male; Oxidative Stress; Pancreatitis; Phosphodiesterase 3 Inhibitors; Rats; Rats, Wistar | 2020 |